Kornimate/medical-research-clean huggingface dataset:
sham feeding post-operative infants

Conditions: Newborn Morbidity; Oral Aversion; Gastroschisis; Bowel Obstruction; Short Bowel Syndrome

Summary: the purpose of this pilot study is to evaluate a feeding technique, sham feeding, to promote adequate oral skills in order to prevent oral aversion and/or poor oral skills due to the delay in oral feeds for surgical reasons. sham feeding is intended for infants who are expected to have a prolonged course without normal enteral feeding by mouth.

there is a lack of literature and research on which to base interventions that intend to preserve and develop oral and motor feeding skills in the post-operative patient population during the critical window of opportunity to establish proper oral skills. due to the lack of positive oral feeding stimuli (i.e. prolonged airway management, nasogastric tubes, and airway and upper gi suctioning), these patients are at risk to develop oral aversions that may negatively impact long-term outcomes. parents in the neonatal intensive care unit (nicu) report feelings of stress and loss of control associated with medical interventions. when normal oral feeding is contraindicated, there may be impairment of parent-child bonding and mothers may be less dedicated to providing milk for the infant. impaired bonding has been shown to affect the parent-child relationship and the child's development long after discharge. sham feeding has been shown to be safe and shorten time to oral feeding in infants with esophageal atresia with delayed esophageal repair. anecdotal evidence from le bonheur suggests that sham feeding in post-operative gastroschisis patients improves parental satisfaction and engagement. there is no literature to describe the use of sham feeding in neonates other than those with esophageal atresia. anecdotal reports from our institution and others institutions suggests that it increases parental engagement and improves parental satisfaction among patients with other bowel pathology. this is a cohort study with historical controls within a single level iv nicu. participants will be offered sham feeding by breast or bottle and observed.

Eligibility criteria:
inclusion criteria: 1. neonates at least 34 weeks post-menstrual age who have a history of gastrointestinal surgery, require no respiratory support more than 2 lpm by nasal cannula, and have an anticipated prolonged course with contraindication to normal oral or enteral feeding. they must have a diagnosis of gastroschisis awaiting return of bowel function, bowel atresia or other obstruction with anticipated feeding contraindication longer than 30 days, or short bowel syndrome intolerant of full intermittent oral feeding. 2. mothers of enrolled neonates exclusion criteria: 1. lack of consent or parental consent. 2. contraindication to sham feeding as determined by the responsible medical provider.
medical physics direct patient care for the improvement of patient understanding of care

Conditions: Malignant Neoplasm

Summary: this phase ii trial studies how well medical physics direct patient care works in improving patients' understanding of their cancer treatment. providing direct physicist-patient interactions and answering patients' questions about their cancer treatment may help patients to understand the care and therefore reduce anxiety and distress during treatment.

primary objective: i. to evaluate whether the medical physics direct patient care initiative (mpdpci) improves anxiety/distress. secondary objective: ii. to assess whether the mpdpci improves patient treatment adherence and overall satisfaction. outline: patients are randomized to 1 of 2 arms. arm i: patients receive printed materials describing the technical aspects of their treatment. arm ii: patients receive printed materials as in arm i. patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.

Eligibility criteria:
inclusion criteria: * medical physicists will be eligible if they care for patients within the gershenson radiation oncology center within the karmanos cancer institute and have completed the patient communication training * are able to read and write in english * are scheduled for curative radiation therapy at the gershenson radiation oncology center exclusion criteria: * none
the use of oxytocin, carbetocin and buccal misoprostol in patients undergoing elective cesarean section (cs)

Conditions: Postpartum Hemorrhage

Summary: the use of oxytocin, carbetocin and buccal misoprostol in patients undergoing elective cesarean section

the use of oxytocin, carbetocin and buccal misoprostol in patients undergoing elective cesarean section in the prevention of uterine atony and postpartum hemorrhage (pph) after caesarean section.

Eligibility criteria:
inclusion criteria: 1. age 18 years or more. 2. gestational age of pregnancy of 37 completed weeks or more. 3. written and signed informed consent by the patient to participate in the study. exclusion criteria: 1. fetal or maternal distress where, due to time constraints, it will not possible and/or appropriate to recruit or randomize. 2. women undergoing caesarean section with general anesthesia are also excluded, because carbetocin is licensed for use with regional anaesthesia only. 3. women planned to have any other type of uterine incision other than transverse lower segment. 4. women with hellp syndrome (hemolysis, elevated liver enzymes, and low platelet count), eclampsia, and epilepsy . 5. women with placental abruption are excluded because there is a higher risk of hemorrhage with this condition and it was therefore felt to be inappropriate to recruit these women. 6. women with thrombocytopenia, known coagulopathies, or receiving anticoagulant therapy. 7. women with history of significant heart disease, a history or evidence of liver, renal, vascular disease or endocrine disease (other than gestational diabetes). 8. women with history of hypersensitivity to oxytocin or carbetocin. 9. women with any severe allergic condition or severe asthma. 10. women with any contraindication to receiving prostaglandins, including known hypersensitivity to misoprostol or other prostaglandins (pgs) or glaucoma. 11. mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.

Keywords: caesarean section, ecbolics, postpartum hemorrhage
microcurrent therapy and low-level laser therapy on wound healing

Conditions: Wound Healing Delayed

Summary: the study aiming to compare between the microcurrent and low-level laser therapy on wound healing

the study designed to compare between the microcurrent and low-level laser therapy on wound healing

Eligibility criteria:
inclusion criteria: * patient recently undergo appendectomy exclusion criteria: * patient with neurological disorders * patient with metabolic disorders
proximal femoral fractures - patient population, risk factors, surgical performance and outcome

Conditions: Proximal Femoral Fracture

Summary: proximal femoral fractures are a typical pathology in elderly patients after a low-energy trauma. this study analyses preexisting risk factors for proximal femoral fractures as well as for failing to reach the previous functional level, difference in outcome between patients with femoral neck fracture compared to those with pertrochanteric fracture, surgical performance and its significance for the functional outcome, as well as the impact of proximal femoral fractures on patients' one-year independence.


Eligibility criteria:
inclusion criteria: * surgery with intramedullary nail type gamma® nail or similar in case of pertrochanteric fractures or * with a partial hip arthroplasty in case of femoral neck fractures exclusion criteria: * clinical follow up at another institution * documented dissent in study participation

Keywords: femoral neck fracture pertrochanteric femoral fracture risk factor for proximal femoral fracture
clinical trial treatment in lupus nephritis

Conditions: Lupus Nephritis

Summary: the treatment of lupus nephritis with cyclophosphamide and steroids changed the prognosis of lupus nephritis in the early '80s. in recent years, alternative regimens have appeared in both the induction and maintenance with similar results at least to those offered by the classic pattern and possibly with fewer side effects, especially for long term. the association of prednison and mycophenolate has created large expectations to that effect, and is part of first-line therapeutic arsenal of lupus nephritis type iii, iv and v. despite the significant advances that have led to these treatments, the likelihood of complete remission after six months remains, according to the series of 8-13% and partial remission do not exceed 60% in papers published. in the last year, two articles have been published supporting the use of triple therapy (prednisone, mycophenolate, cyclosporine) in poor prognosis of lupus nephritis with hopefully better results than those obtained previously. in this study we try to compare the effectiveness of triple therapy, the therapy is now considered standard (prednisone, mycophenolate) in patients with lupus nephritis type iii-iv-v

asd

Eligibility criteria:
inclusion criteria: * age \> 18 years old * patients diagnosed sle with renal type iii-iv-v confirmed by renal biopsy done in the last 6 months * proteinuria \> 2 g/24 hours and hematuria (\> 5 h / field) * mdrd4 egfr \> 60 ml/min/1.73m2 * participant is willing and able to give informed consent for participation in the study exclusion criteria: * central nervous system les involvement or any other vital organ * active infection * use of mycophenolic acid, mycophenolate mofetil, cyclosporine or tacrolimus in the last 6 months * no adherence * women of childbearing age not using appropriate contraceptive methods. * positive pregnancy test * anasarca * malignancy or cancer history (except basal cell skin carcinomas) * patient participating in another study with an investigational drug or have participated within 28 days prior to entry into this study

Keywords: lupus nephritis therapy cyclosporin mycophenolic acid
comparison of atorvastatin and pitavastatin on the effect of hba1c in ami patients with abnormal glucose metabolism

Conditions: Acute Myocardial Infarction; Glucose Metabolism Disorders

Summary: different types of statins show different influences on glycometabolism. there are no systemic analyses of the effects that statins exert on the metabolism of glucoses so far in china. this research aims to compare impacts on the glycometabolism of pitavastatin in ami patients with atorvastatin and to accumulate data for guiding the utilization of statins.

general study design: this study is a prospective, multicenter, open and randomized controlled clinical trial, which utilize online registration database of cami to do the enrollment, randomization and follow-up. we will select 14 of the centers to compete into the group. the researchers used a central randomized distribution system to prescribe medication for patients. follow the method of drug administration approved by the state drug administration department, we will estimate the efficacy and safety of treatment at the following timing: baseline, one month and six months after treatment.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed acute myocardial infarction. 2. diabetes or pre-diabetes. 3. the patient signed informed consent. exclusion criteria: 1. a clear history of chronic liver disease, or abnormal liver function (alt/ast\>1.5×uln). 2. there is evidence of active inflammatory myopathy or ck\>3×uln. 3. being allergic to statins or severe side effects were caused by taking statins(including myolysis). 4. combined with hypothyroidism, nephrotic syndrome, alcoholism, pancreatitis, lupus erythematosus. 5. all patients who had a clear adverse reaction to the statins. 6. possibility of pregnancy, pregnant or lactating patients. 7. there may be limited medical history of subjects who may can not complete their treatment during the study period. 8. undergoing or planning to functional renal transplantation. 9. the life expectancy is no more than half a year. 10. patients who are taking birth control pills, steroid hormones and imidazole drugs. 11. patients who have participated in clinical trials of other drugs within 1 month, or known that clinical follow-up or research on drug compliance poorly. 12. patients are not fit to be tested according to the researchers.

Keywords: pitavastatin atorvastatin hba1c ldl-c
clinical practices for treating severe malaria caused by p. falciparum

Conditions: Malaria, Falciparum; Plasmodium Falciparum; Antimalarials; Artemisinins; Treatment Outcome; Drug Therapy, Combination; Retrospective Studies; Hospitalization

Summary: this study looks at how doctors in three hospitals in france treat patients with a serious form of malaria caused by plasmodium falciparum. it focuses on cases where the level of malaria parasites in the blood is 4% or higher. the study will compare how often a type of medicine called act (artemisinin-based combination therapy) is used on its own instead of the usual first-choice treatment (intravenous artesunate), and whether act works just as well. it will also check how well patients recover, whether they have complications, and how long they stay in the hospital.


Eligibility criteria:
inclusion criteria: * adult patients aged 18 years or older. * diagnosis of plasmodium falciparum malaria with a parasitemia level ≥ 4%. exclusion criteria: - patients under 18 years old
vitamin a and azithromycin for acne vulgaris

Conditions: Acne Vulgaris

Summary: patients seen with acne lesions not having responded to existing treatments will be offered a placebo or a topical preparation consisting of vitamin a usp with or without azithromycin for a duration of 4-6 months usp for the objective of resolving the lesions without systemic side effects and via weekly follow-ups.

the concentrations of the active ingredients is based on the enclosed articles and the formulations have been modified with an objective of minimizing the side effects.

Eligibility criteria:
inclusion criteria: * patients with active lesions exclusion criteria: * patients on a treatment * asymptomatic patients
estimating prevalence of covid-19 infection and sars-cov-2 antibodies in ms patients

Conditions: Multiple Sclerosis; Covid19

Summary: this non-interventional, biospecimen collection study is designed to help us better understand whether ms patients have impaired immune defenses to covid-19 infection. the potential influence of immune modulating medications for ms will be considered through these exploratory studies. this study is also designed to provide context for interpretation of anti-sars cov2 serologies in ms patients during convalescence from covid-19 infection.


Eligibility criteria:
inclusion criteria (part a and b): ● patient is outside of infectious period of covid-19 defined as follows: * patient with mild to moderate illness who are not severely immunocompromised: * at least 10 days have passed since symptoms first appeared and * at least 24 hours have passed since last fever without the use of fever-reducing medications and * symptoms (e.g. cough, shortness of breath) have improved * patient with severe to critical illness or who are severely immunocompromised: * at least 10 days and up to 20 days have passed since symptoms first appeared * at least 24 hours have passed since last fever without the use of fever-reducing medications and * symptoms (e.g. cough, shortness of breath) have improved * clinician-diagnosed ms treated or untreated with an approved dmt, * ages 18 to 60, * edss 0 - 7, * able to give informed consent, * able to complete, or have someone help complete the patient questionnaire, * no high dose steroids, or ivig, or plex use within 3 months of blood sample, * no convalescent plasma and/or polyclonal antibody treatments for covid-19 within 3 months of blood sample collection. inclusion criteria (part b only) * covid-19 positive patients, who received ocr within 6 months of covid 19 infection, * edss 0 - 6. inclusion critera (redraws only) * completed standard of care covid-19 vaccination series * on ocrevus, glatiramer, interferon b, or not on any treatment disease-modifying treatment at the time of vaccination. exclusion criteria (part a and b): * concurrent immunosuppressive therapy, active systemic cancer, primary or acquired immunodeficiency (i.e., cvid, hiv infection), * active drug or alcohol abuse, * other anti-cd20 therapy apart from ocr, * uncontrolled diabetes mellitus, * end-organ failure (cardiac, pulmonary, renal, hepatic), * systemic lupus erythematosus (sle). exclusion criteria (part b only): * edss \>6, * active infection (e.g., hepatitis). exclusion criteria (healthy controls sample) * concurrent immunosuppressive therapy, active systemic cancer, primary or acquired immunodeficiency (e.g. cvid, hiv infection), * active ongoing drug or alcohol abuse, * age \>60 or \<18, * uncontrolled diabetes mellitus, * end-organ failure (cardiac, pulmonary, renal, hepatic), * sle * no high dose steroids, or intravenous immunoglobulin (ivig) or plasma exchange (plex) use within 3 months of blood sample collection, * no convalescent plasma and/or polyclonal antibody treatments for covid-19 within 3 months of blood sample collection.

Keywords: disease-modifying therapy
a 6-month extension study of oto-104 in meniere's disease

Conditions: Meniere's Disease

Summary: this is an open-label extension study of a single intratympanic injection of oto-104 given every 3 months for a total of 2 injections. subjects must have completed either otonomy study 104-201102 (phase 2b study of oto-104) or 104-201506 (phase 3 study of oto-104) in order to be eligible for this open-label extension study.


Eligibility criteria:
inclusion criteria includes, but is not limited to: * subject has completed the oto-104 phase 2b (104-201102) or phase 3 (104-201506) clinical study. * subject has a diagnosis of definite unilateral meniere's disease by 1995 aao-hns criteria exclusion criteria includes, but is not limited to: * subject is pregnant or lactating. * subject has a history of immunodeficiency disease. * subject has experienced an adverse reaction to intratympanic injection of steroids.
effects of mediterranean diet and naltrexone/bupropion treatment in obese breast cancer patients

Conditions: Breast Cancer; Obesity; Overweight

Summary: obesity among breast cancer survivors is known to be associated with recurrence and other co-morbidities. however, there have been no studies on weight reduction program combining diet and anti-obesity drug for obese breast cancer survivors. the purpose of this randomized clinical trial is to examine the effects of mediterranean diet and naltrexone/bupropion treatment on inflammation and metabolic risk factors in overweight or obese breast cancer patients after breast cancer treatment.


Eligibility criteria:
inclusion criteria: * female, 20 to 65 years of age * diagnosed with breast cancer stage ⅰ-ⅲ, and have completed cancer treatment including breast surgery and/or adjuvant chemotherapy, radiotherapy, hormonal therapy * bmi ≥25 kg/m2, or bmi ≥23 kg/m2 with one or more of the metabolic risk factors (waist circumference ≥80 cm, fasting glucose ≥100 mg/dl, bp ≥130/85 mmhg, hdl-cholesterol \<50 mg/dl or controlled diabetes, hypertension, dyslipidemia with medications) * if woman of child bearing potential, agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug * able to speak and read korean * able to comply with all required study procedures and schedule * willing and able to give written informed consent exclusion criteria: * participants with cancer recurrence or metastasis * participants with uncontrolled hypertension (systolic blood pressure (sbp) \>180 mmhg, or diastolic blood pressure (dbp) \>120 mmhg) * participants with hepatic disease (aspartate aminotransferase (ast)/alanine aminotransferase (alt) \>3 x institutional upper limit of normal) or renal disease (serum creatinine \>2.0 mg/dl) * participants with significant cardiovascular disease or stroke * participants with history of seizures * participants with serious psychiatric illness, including bipolar disorder, schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation * participants who are taking medications such as monoamine oxidase (mao) inhibitors, opioid-containing medications, other naltrexone or bupropion containing medications, and tamoxifen * current smokers or use of nicotine replacement products in the previous 6 months * pregnant or breast-feeding women * any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study
mass response of tumor cells as a biomarker for rapid therapy guidance (traverartgx)

Conditions: Pleural Effusion, Malignant; Ascites, Malignant; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Renal; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Neuroendocrine; Carcinoma, Thymic; Carcinoma, Pancreatic; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma Bladder; Carcinoma of Unknown Primary; Carcinoma of the Head and Neck; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma of the Bladder; Carcinoma of Esophagus; Carcinoma of the Nasopharynx; Carcinoma of the Penis; Carcinoma of the Cervix; Carcinoma of the Anus; Carcinoma of the Vulva; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Cholangiocarcinoma; Melanoma; Mesothelioma; Pancreatic Cancer

Summary: the primary objective of this study, sponsored by travera inc. in massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.


Eligibility criteria:
inclusion criteria: 1. patient is ≥18 years of age 2. written informed consent provided by patient 3. diagnosis of any kind of carcinoma 4. malignant fluid (e.g. pleural effusion or ascites) drainage or tumor tissue resection or tumor tissue needle biopsy is clinically indicated as part of soc 5. proceeding onto therapy for treatment 6. informed consent obtained for the xcelsior longitudinal outcomes registry (nct03793088) exclusion criteria: 1. lack of informed consent 2. unable to obtain sufficient sample

Keywords: breast cancer lung cancer nsclc occult cancer ovarian cancer melanoma mesothelioma gastrointestinal stromal tumor gastric cancer colon cancer cervical cancer
carbohydrates to prevent hypoglycaemia during physical activity in patients with type 1 diabetes

Conditions: Hypoglycaemia

Summary: backgrounds/aims: it was the aim to prospectively study the optimum regime of "preventive" carbohydrate administration for prevention of hypoglycaemic episodes during a standardized bout of physical activity.

research design and methods: 24 patients with type 1 diabetes participated in one experiment without physical activity and in three experiments with a 4 km, 60 min hike starting at 2 p.m., either administering 2 x 10 g or 2 x 20 g carbohydrates (muesli bars) before starting and at 30 min (during the hike). plasma glucose was determined with a laboratory method and additional carbohydrates needed to treat hypoglycaemia between 2 and 8 p.m. were recorded.

Eligibility criteria:
inclusion criteria: type 1 diabetes mellitus, 18-75 years, bmi 18-35 kg/m², diabetes duration \> 1 year exclusion criteria: general bad health status, malignant diseases, systemic glucocorticoid treatment, coronary heart disease, uncontrolled arterial hypertension, acute infection diseases, diseases of liver or kidney with significant organ malfunction, abuse of alcohol or other drugs, participation in another trial in the last 3 months -

Keywords: carbohydrate, hypoglycemia